Country: United States
Language: English
Source: NLM (National Library of Medicine)
VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG)
Orchid Healthcare (a division of Orchid Chemicals & Pharmaceuticals Ltd.)
VENLAFAXINE HYDROCHLORIDE
VENLAFAXINE 37.5 mg
ORAL
PRESCRIPTION DRUG
Venlafaxine hydrochloride extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Venlafaxine hydrochloride extended-release capsules in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessne
Venlafaxine hydrochloride extended-release capsules are available as follows: 37.5 mg: Grey cap/Caramel body, “Size 3” hard gelatin capsules with imprinting “105” on body and “VXR” on cap with red ink, filled with white to off white pellets. NDC 68820-105-39, bottle of 15 capsules in unit of use package. NDC 68820-105-19, bottle of 30 capsules in unit of use package. NDC 68820-105-22, bottle of 90 capsules in unit of use package. NDC 68820-105-10, bottle of 100 capsules. NDC 68820-105-03, blister of 10 capsules. NDC 68820-105-11, carton of 10 blister strips of 10 capsules each. 75 mg: Caramel cap/Caramel body, “Size 1” hard gelatin capsules with imprinting “106” on body and “VXR” on cap with red ink, filled with white to off white pellets. NDC 68820-106-39, bottle of 15 capsules in unit of use package. NDC 68820-106-19, bottle of 30 capsules in unit of use package. NDC 68820-106-22, bottle of 90 capsules in unit of use package. NDC 68820-106-10, bottle of 100 capsules. NDC 68820-106-03, blister of 10 capsules. NDC 68820-106-11, carton of 10 blister strips of 10 capsules each. 150 mg: Reddish Brown cap/Reddish Brown body, Size “0el” hard gelatin capsules with imprinting “107” on body and “VXR” on cap with white ink, filled with white to off white pellets. NDC 68820-107-39, bottle of 15 capsules in unit of use package. NDC 68820-107-19, bottle of 30 capsules in unit of use package. NDC 68820-107-22, bottle of 90 capsules in unit of use package. NDC 68820-107-10, bottle of 100 capsules. NDC 68820-107-03, blister of 10 capsules. NDC 68820-107-11, carton of 10 blister strips of 10 capsules each. Store at controlled room temperature, 20° to 25°C (68° to 77°F). The unit of use package is intended to be dispensed as a unit.
Abbreviated New Drug Application
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE Orchid Healthcare (a division of Orchid Chemicals & Pharmaceuticals Ltd.) ---------- MEDICATION GUIDE Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions Read the Medication Guide that comes with your or your family member’s antidepressant medicine. This Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. Talk to your, or your family member’s, healthcare provider about: • all risks and benefits of treatment with antidepressant medicines • all treatment choices for depression or other serious mental illness What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions? 1.Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment. 2.Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. • Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. • Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms. Call a healthcare provider right away if you or your family member has a Read the complete document
VENLAFAXINE HYDROCHLORIDE - VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE ORCHID HEALTHCARE (A DIVISION OF ORCHID CHEMICALS & PHARMACEUTICALS LTD.) ---------- VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES RX ONLY SUICIDALITY AND ANTIDEPRESSANT DRUGS ANTIDEPRESSANTS INCREASED THE RISK COMPARED TO PLACEBO OF SUICIDAL THINKING AND BEHAVIOR (SUICIDALITY) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS IN SHORT-TERM STUDIES OF MAJOR DEPRESSIVE DISORDER (MDD) AND OTHER PSYCHIATRIC DISORDERS. ANYONE CONSIDERING THE USE OF VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES OR ANY OTHER ANTIDEPRESSANT IN A CHILD, ADOLESCENT, OR YOUNG ADULT MUST BALANCE THIS RISK WITH THE CLINICAL NEED. SHORT-TERM STUDIES DID NOT SHOW AN INCREASE IN THE RISK OF SUICIDALITY WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS BEYOND AGE 24; THERE WAS A REDUCTION IN RISK WITH ANTIDEPRESSANTS COMPARED TO PLACEBO IN ADULTS AGED 65 AND OLDER. DEPRESSION AND CERTAIN OTHER PSYCHIATRIC DISORDERS ARE THEMSELVES ASSOCIATED WITH INCREASES IN THE RISK OF SUICIDE. PATIENTS OF ALL AGES WHO ARE STARTED ON ANTIDEPRESSANT THERAPY SHOULD BE MONITORED APPROPRIATELY AND OBSERVED CLOSELY FOR CLINICAL WORSENING, SUICIDALITY, OR UNUSUAL CHANGES IN BEHAVIOR. FAMILIES AND CAREGIVERS SHOULD BE ADVISED OF THE NEED FOR CLOSE OBSERVATION AND COMMUNICATION WITH THE PRESCRIBER. VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES IS NOT APPROVED FOR USE IN PEDIATRIC PATIENTS. (SEE WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: INFORMATION FOR PATIENTS, AND PRECAUTIONS: PEDIATRIC USE) DESCRIPTION Venlafaxine hydrochloride extended-release capsule is for oral administration that contains venlafaxine hydrochloride, a structurally novel antidepressant. It is designated (R/S)-1-[2-(dimethylamino)-1-(4- methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α-[(dimethylamino)methyl]-p- methoxybenzyl] cyclohexanol hydrochloride and has the empirical formula of C H NO HCl. Its molecular weight is 313.87. The structural formula is shown below. Venlafaxine Read the complete document